Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* OAM-naïve or have been taking OAM monotherapy for at least 3 months~* Glycosylated Hemoglobin (HbA1c) value of ≥7.0% to ≤10.5% for OAM-naïve participants or ≥6.5% to ≤10.0% for participants taking OAM monotherapy~* Adult men or adult non-pregnant, non-breastfeeding women~* Stable weight (±5%) ≥3 months prior to screening~* Body mass index (BMI) of ≥19.0 to ≤35.0 kilograms per square meter (kg/m\^2)~Exclusion Criteria:~* Have type 1 diabetes mellitus~* Have previously been treated with a glucagon-like peptide-1 (GLP-1) receptor agonist, GLP-1 analog, or any other incretin mimetic during the 3 months before screening~* Are currently taking dipeptidylpeptidase-IV (DPP-IV) inhibitor and thiazolidinediones (TZD) during the 3 months before screening~* Have gastric emptying abnormality~* Have cardiac disorder defined as unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, heart failure, arrhythmia, transient ischemic attack, or stroke~* Have poorly controlled hypertension (systolic blood pressure above 160 millimeters of mercury \[mmHg\] or diastolic blood pressure above 95 mmHg)~* Have impaired liver function~* Have impaired kidney function~* Have history of chronic pancreatitis or acute pancreatitis~* Have a serum calcitonin ≥20 picogram/milliliter (pg/mL)~* Have a personal or family history of medullary C-cell hyperplasia, focal hyperplasia, carcinoma or multiple endocrine neoplasia type 2 (MEN 2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.5 mg Dulaglutide (Type: EXPERIMENTAL): 1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
- 0.75 mg Dulaglutide (Type: EXPERIMENTAL): 0.75 mg dulaglutide administered as one SC injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
- Glimepiride (Type: ACTIVE_COMPARATOR): 1 to 3 mg per day (mg/day) glimepiride administered orally as one to three capsules per day plus one SC injection of placebo once-weekly for blinding purposes for up to 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).